Apellis Pharmaceuticals, Inc.
APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-relaā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$21.59
Price+2.81%
$0.59
1Y
Price
Market Cap
$2.732b
Mid
Price/Earnings 3y Avg5y Avg
60x
Premium
Premium
Financials Overview
Key metrics over the past few years+49.7%
EBITDA Margin+47.0%
Net Profit Margin+23.6%
Free Cash Flow MarginRevenue
$1.016b
+30.1%
1y CAGR+184.3%
3y CAGR+141.6%
5y CAGREarnings
$44.986m
+122.7%
1y CAGR+68.1%
3y CAGR+54.2%
5y CAGREPS
$0.35
+121.9%
1y CAGR+71.2%
3y CAGR+61.0%
5y CAGRBook Value
$401.168m
$1.059b
Assets$657.555m
Liabilities$475.374m
DebtDebt to Assets
44.9%
5.1x
Debt to EBITDAFree Cash Flow
$78.638m
+189.1%
1y CAGR+86.2%
3y CAGR+66.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company